Moreover, LPAR2 and LPAR5 mediate resistance of colon cancer cells to 5′-fluoro-uracil [134], whilst in the same tumour type, LPA enhances resistance to EZH2 inhibitors through LPAR2 [135], suggesting that co-targeting of ATX/LPA/LPAR2 and EZH2 might be beneficial for colon cancer treatment. This evidence concerns the gene LPAR2 and colonic neoplasm.